Rose is an associate editorial director at The American Journal of Managed Care® (AJMC®).
She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on LinkedIn.
Response to Immunotherapy Linked With Improved Liver Function in Advanced HCC
Although the amount of real-world evidence demonstrating the safety and efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma (HCC) has been growing, data on liver function evolution as a prognostic factor for overall survival are lacking.
Survey Shows Importance of Discussing, Treating Endocrine Effects of Steroids for DMD
Results from a national survey of patients with Duchenne muscular dystrophy (DMD) and their families found that patients and families want to be informed early about endocrine complications associated with glucocorticoid treatment.
AxSpA Treatment Intensification in Practice Linked With Higher ASDAS Cutoff Than Recommended
In the clinical practice setting, intensifying treatment for axial spondyloarthritis (axSpA) is associated with a higher Ankylosing Spondylitis Disease Activity Score (ASDAS) cutoff value than recommended, new research found.
CBO Report Assesses Budgetary Effects of Potential Policies to Increase Hepatitis C Treatment
Health care spending avoided by increased hepatitis C treatment could more than offset direct spending on increased treatment, according to a new report from the Congressional Budget Office (CBO).
Dr Catherine Diefenbach on the Evolving DLBCL Treatment Landscape
Catherine Diefenbach, MD, an American Society of Hematology expert and director of the Clinical Lymphoma Program at NYU Langone's Perlmutter Cancer Center, discussed the evolving state of diffuse large B-cell lymphoma (DLBCL) therapeutics and exciting areas of research.
Barriers to DMD Care Access and How Policy Change Can Support Patients: Dr Migvis Monduy
Migvis Monduy, MD, medical director of Neuromuscular and Movement Disorders Programs at Nicklaus Children's Hospital, discussed challenges in Duchenne muscular dystrophy (DMD) treatment access and how policy changes may support patients with DMD.
Dr Amit Singal on the Improving Outlook for HCC and How to Choose Treatments
Amit Singal, MD, medical director of the Liver Tumor Program at UT Southwestern Medical Center, discussed the current outlook for patients with hepatocellular carcinoma (HCC) and how to choose between therapies.
Camrelizumab Plus Rivoceranib Improves Survival vs Standard First-Line Care for HCC
In the final overall survival analysis of the phase 3 CARES-310 trial, frontline camrelizumab plus rivoceranib continued to show clinically meaningful survival benefits vs sorafenib for hepatocellular carcinoma (HCC).